Ana Peña

ORCID: 0000-0001-9684-837X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neuroendocrine regulation and behavior
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Receptor Mechanisms and Signaling
  • Acute Myocardial Infarction Research
  • Atrial Fibrillation Management and Outcomes
  • Venous Thromboembolism Diagnosis and Management
  • Blood properties and coagulation
  • Circadian rhythm and melatonin
  • Diabetes Treatment and Management
  • Electrolyte and hormonal disorders
  • Lipoproteins and Cardiovascular Health
  • Blood Coagulation and Thrombosis Mechanisms
  • Neuropeptides and Animal Physiology
  • Chemical Reaction Mechanisms
  • Blood groups and transfusion
  • Protease and Inhibitor Mechanisms
  • Blood transfusion and management
  • Coronary Interventions and Diagnostics
  • Sphingolipid Metabolism and Signaling
  • Lipid Membrane Structure and Behavior
  • Ion Transport and Channel Regulation
  • Diabetes Management and Research
  • Stress Responses and Cortisol
  • Eicosanoids and Hypertension Pharmacology
  • Inflammatory mediators and NSAID effects

Hospital Universitario Miguel Servet
2024

Instituto de Salud Carlos III
2023

Hospital Curry Cabral
2022

Hospital El Bierzo
2021

Cleveland Clinic Florida
2020

Universidad de Jaén
2015

Sorbonne Université
2009-2012

Assistance Publique – Hôpitaux de Paris
2008-2012

Pitié-Salpêtrière Hospital
2010-2012

Inserm
2004-2011

Clopidogrel loading has mostly been studied in clopidogrel-naïve patients. Whether clopidogrel-treated patients readmitted for an acute coronary syndrome or percutaneous intervention can benefit from a new load of clopidogrel and at what dose remain unknown. Our aim was to evaluate the impact 3 different strategies administration 900 mg already treated with maintenance 75 least 7 days on residual platelet aggregation.Patients long term by mg/d were assigned receive first 300, 600, 4 hours...

10.1161/circulationaha.108.776757 article EN Circulation 2008-09-03

Protease nexin-1 (PN-1) is a serpin that inhibits plasminogen activators, plasmin, and thrombin. PN-1 barely detectable in plasma, but we have shown recently present within the α-granules of platelets.In this study, role platelet fibrinolysis was investigated with use human platelets incubated blocking antibody from PN-1-deficient mice. We showed by using fibrin-agar zymography fibrin matrix inhibited both generation plasmin fibrin-bound tissue activator activity itself. Rotational...

10.1161/circulationaha.110.000885 article EN Circulation 2011-03-15

AimsThe underlying mechanisms leading to recurrent ischaemic events or mortality after red blood cell (RBC) transfusion in anaemic acute coronary syndrome patients are poorly understood. The aim of this paper is determine whether RBC increases platelet activation and aggregation.

10.1093/eurheartj/ehq209 article EN European Heart Journal 2010-06-29

Leishmaniasis is an endemic parasitic disease in at least 98 countries. In Spain, it considered a zoonosis caused by Leishmania infantum, with annual incidence of 0.62 cases/100,000 inhabitants. The predominant clinical manifestations are the cutaneous (CL) and visceral forms (VL), diagnosis performed parasitological, serological, molecular tests. At WHO Collaborating Center for (WHOCCLeish), routine diagnostic tests based on nested PCR (Ln-PCR), culture, serological To simplify our...

10.1128/spectrum.03354-22 article EN cc-by Microbiology Spectrum 2023-04-04

Objective This study aims to assess the impact of integrating ATLAS 2030 into conventional therapy regimen for children with Cerebral Palsy (CP) compared alone regarding gross motor function, range motion (ROM) and spasticity. Design A non-randomized controlled trial conducted in outpatient rehabilitation settings special education schools, following recommendations by Consolidated Standards Reporting Trials (CONSORT) statement. Participants Thirty CP divided intervention control groups....

10.3389/fped.2024.1398044 article EN cc-by Frontiers in Pediatrics 2024-07-29

Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid capable of regulating critical physiological and pathological functions. Here, we report for the first time that S1P stimulates aldosterone secretion in cells zona glomerulosa adrenal gland. Regulation important because this hormone controls electrolyte fluid balance implicated cardiovascular homeostasis. S1P-stimulated was dependent upon protein kinase C (PKC) isoforms alpha delta extracellular Ca2+, it inhibited by pertussis toxin...

10.1194/jlr.m500510-jlr200 article EN cc-by Journal of Lipid Research 2006-03-23

We show here for the first time that sphingosine‐1‐phosphate (Sph‐1‐P) stimulates cortisol secretion in zona fasciculata cells of bovine adrenal glands. This effect was dependent upon protein kinase C (PKC) and extracellular Ca 2+ , inhibited by pertussis toxin. Sph‐1‐P activated phospholipase D (PLD) through a toxin‐sensitive mechanism, also involving PKC. Primary alcohols, which attenuate formation phosphatidic acid (the product PLD), cell‐permeable ceramides, inhibit PLD, blocked...

10.1016/s0014-5793(02)03882-6 article EN FEBS Letters 2003-01-10

Starting from the 2.8-A resolution x-ray structure of bovine rhodopsin, three-dimensional molecular models complexes between arginine vasopressin and two receptor subtypes (V1a, V1b) have been built. Amino acid sequence alignment docking studies suggest that four key residues (1.35, 2.65, 4.61, 5.35) fine tune binding related peptide agonists to both subtypes. To validate these predictions, a series single or double mutants were engineered at V1a V1b tested for their functional properties....

10.1210/me.2006-0202 article EN Molecular Endocrinology 2006-11-03

Recently, we synthesized and characterized the first selective V(1b) vasopressin (VP)/oxytocin receptor agonist, d[Cha(4)]arginine vasopressin. However, this agonist was only for human receptors. We thus decided to design a rodent species. started from previous observations showing that modifying [deamino(1),Arg(8)]VP in positions 4 8 altered rat VP/oxytocin selectivity. series of 13 analogs modified 8. Among them, one seemed very promising, d[Leu(4), Lys(8)]VP. In paper, describe its...

10.1210/en.2006-1633 article EN Endocrinology 2007-05-11

The neurohypophyseal peptides arginine vasopressin (AVP) and oxytocin (OT) mediate a wide variety of peripheral central physiological behavioral effects by acting on four different G-protein coupled receptors, termed V1a (vascular), V1b (pituitary), V2 (renal), OT (uterine). We recently reported that d[Cha4]AVP (A), d[Leu4]AVP (B), d[Orn4]AVP (C), d[Arg4]AVP (D) have high affinity are selective agonists for the human receptor. However, A−D were subsequently shown to be potent antidiuretic in...

10.1021/jm060928n article EN Journal of Medicinal Chemistry 2007-01-20

In the kidney, tissue oxygen tension is comparatively low and this renders organ more prone to hypoxic injury. fact, hypoxia has a central role in development progression of renal disease. The recovery from situation dependent on degree which sublethally damaged cells restore normal function. master regulator response hypoxia-inducible factor-1 (HIF-1). HIF-1 activity depends HIF-1α subunit level regulated by oxygen, nitric oxide (NO), reactive species mTOR. Given antioxidant antinitrosative...

10.1039/c5fo00928f article EN Food & Function 2015-11-10

The glutamine4 residue in [deamino-Cys1]arginine vasopressin (dAVP) was replaced by a broad series of aliphatic, aromatic, polar, and charged amino acids to give the following peptides: d[Gly4]AVP (1), d[Ala4]AVP (2), d[Abu4]AVP (3), d[Nva4]AVP (4), d[Nle4]AVP (5), d[Leu4]AVP (6), d[Ile4]AVP (7), d[Thi4]AVP (8), d[Phe4]AVP (9), d[Tyr4]AVP (10), d[Trp4]AVP (11), d[Asn4]AVP (12), d[Ser4]AVP (13), d[Thr4]AVP (14), d[Dap4]AVP (15), d[Dab4]AVP (16), d[Orn4]AVP (17), d[Lys4]AVP (18), d[Arg4]AVP...

10.1021/jm030611c article EN Journal of Medicinal Chemistry 2004-03-30

Summary The FXIII-A Leu34 genetic variant increases and accelerates fibrin stabilisation; however, its association with premature coronary artery disease (CAD) thrombotic events remains controversial. FXIII Val34Leu genotype was determined in 242 young individuals (<45 years old) who survived a myocardial infarction (MI) healthy controls matched for age gender. We evaluated effect on longterm clinical outcome defined as composite of cardiovascular death, recurrent MI urgent...

10.1160/th11-01-0027 article EN Thrombosis and Haemostasis 2011-01-01

In mammals, the vasopressin V(1b) receptor (V(1b)-R) is known to regulate ACTH secretion and, more recently, stress and anxiety. The characterization of molecular determinant responsible for its pharmacological selectivity was made possible by recent discovery first antagonist, SSR149415. Based upon structure crystallized bovine rhodopsin, we established a three-dimensional model interaction between human V(1b)-R (hV(1b)-R) Four amino acids located in distinct transmembrane helices (fourth,...

10.1210/me.2004-0124 article EN Molecular Endocrinology 2004-07-30

Abstract Preliminary data in Europe have suggested a reduction prematurity rates during the COVID-19 pandemic, implying that contingency measures could an impact on rates. We designed population-based prevalence proportion study to explore potential link between national lockdown and change preterm births stillbirths. Adjusted multivariate analyses did not show any decrease proportions period with respect whole pre-lockdown or comparison periods (2015-2019): 6.5% (95%CI 5.6-7.4), 6.6%...

10.21203/rs.3.rs-170616/v1 preprint EN cc-by Research Square (Research Square) 2021-02-04
Coming Soon ...